InVision Medical Technology · Apr 2026
InVision announced a partnership with Dandelion Health to run its echo AI on Dandelion's Clinical AI Marketplace, generating up to 30x more cardiac measurements per patient from raw echocardiogram data.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Y Combinator-backed medical technology company building FDA-cleared AI software for echocardiography and cardiac imaging, focused on automating measurements, structured reporting, and disease detection in existing hospital workflows.
Primary product
InVision Precision LVEF
Founded
2022
Headquarters
Los Angeles, California, United States
Team size
1-10
Industry
Medical Technology
Sub-industry
AI echocardiography software (Software as a Medical Device)
Offices
9702 Cisco Street, Los Angeles, California 90034, United States (public business/FDA-listed location)
1497 Samedra Street, Sunnyvale, California 94087, United States (FDA establishment registration / correspondent address)
Business model
Software as a Medical Device (SaMD)
enterprise B2B software
reimbursable clinical diagnostics
clinical trial / core lab services
Funding
Stage
pre-seed
Total raised
$500K
Latest round
Pre-Seed Convertible Note · Aug 2022
Latest amount
$500K
Aug 2022 · Y Combinator
People & investors
Work & culture
Clinician- and researcher-led, evidence-driven, and regulatory-conscious; the public materials emphasize peer-reviewed validation, workflow integration, and close collaboration between clinical and commercial teams.
Product & market
Pricing
Enterprise pricing and reimbursement-backed clinical deployment; some products are positioned around CPT Category III code 0932T, while demos/briefings are offered for sales-led deployment.
Differentiators
- —Founders authored foundational echo-AI research and are practicing clinicians/computer scientists
- —FDA 510(k)-cleared products already in market
- —Blinded, randomized prospective clinical trial evidence for Precision LVEF
- —Reimbursement path via CPT Category III code 0932T
- —Integrates into existing PACS, Epic, and standard DICOM workflows
- —Multi-product platform spanning LVEF, cardiac amyloid, cirrhosis, and reporting
- —Uses large echocardiography datasets and published foundation models
- —Live deployments and partner channels such as HeartLab and Dandelion Health
Technology
DICOM echocardiography
PACS integration
Epic EHR integration
structured reporting workflows
vision-language foundation models
21 CFR Part 11-style audit trails
FDA 510(k) cleared SaMD
blinded randomized clinical trial evidence
Customers
hospital health systems
echo labs
cardiologists
sonographers
clinical trial sponsors
life sciences companies
medical device / pharma partners
Competitors
Ultromics
Us2.ai
Caption Health
EchoIQ
UltraSight
Scale & contact
Estimated revenue
$2M-$5M (GetLatka estimates ~$2.1M ARR)
Estimated monthly visits
1.5K
Latest news
InVision Medical Technology · Nov 2025
InVision said the FDA granted Breakthrough Device status to Precision Cirrhosis, its opportunistic detection tool for end-stage liver disease from routine echocardiography.
InVision Medical Technology · May 2025
InVision announced FDA 510(k) clearance for its cardiac amyloidosis detection SaMD, developed with support from Alexion, AstraZeneca Rare Disease.
InVision Medical Technology · Jul 2024
The company announced CPT Category III code 0932T, creating a reimbursement pathway for AI-assisted cardiac amyloidosis screening on echocardiography.
InVision Medical Technology · May 2024
InVision announced FDA 510(k) clearance for its automated left ventricular ejection fraction software for adult echocardiography.
Jobs and careers at InVision Medical Technology
1 job at InVision Medical Technology
Executive Producer
On-site
eXperience
Walnut Creek, CA; Chicago, IL; New York, NY
1y ago
On-site
Full-time